Last reviewed · How we verify
pemetrexed, cisplatin and CBP501
At a glance
| Generic name | pemetrexed, cisplatin and CBP501 |
|---|---|
| Also known as | Arm A |
| Sponsor | CanBas Co. Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II) (PHASE1, PHASE2)
- Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- pemetrexed, cisplatin and CBP501 CI brief — competitive landscape report
- pemetrexed, cisplatin and CBP501 updates RSS · CI watch RSS
- CanBas Co. Ltd. portfolio CI